Amgen vs BP: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amgen and BP side by side

1. 1901BP

   D'Arcy Persian Concession

   William Knox D'Arcy obtains a 60-year oil concession from the Shah of Persia covering about 480,000 square miles, roughly three-quarters of the country, in exchange for £20,000 in cash, £20,000 in shares and 16% of annual profits.

2. 1908BP

   Discovery of Oil at Masjid-i-Suleiman

   After seven years of expensive and largely unsuccessful drilling, field manager George Reynolds strikes oil at Masjid-i-Suleiman in south-west Persia on May 26, 1908. It is the first commercial oil discovery in the Middle East.

3. 1909BP

   Anglo-Persian Oil Company Incorporated

   The Anglo-Persian Oil Company is formally incorporated in April 1909, with William Knox D'Arcy and the Burmah Oil Company as principal backers.

4. 1914BP

   British Government Acquires 51% Stake

   At the urging of Winston Churchill, First Lord of the Admiralty, the British government pays ~$2.9 million (£2.2 million) for a 51% stake in Anglo-Persian and signs a long-term fuel-oil supply contract for the Royal Navy, which is converting its fleet from coa…

5. 1954BP

   Renamed British Petroleum

   Following the 1953 resolution of the Iranian nationalization crisis and the Shah's restoration to power, the company renames itself British Petroleum Company.

6. 1970BP

   North Sea Forties Field Discovery

   BP discovers the Forties field in the UK North Sea, one of the largest oil fields ever found in British waters. Together with Alaska's Prudhoe Bay, it gives BP politically secure production just as Middle Eastern governments take control of their oil.

7. 1980Amgen

   Applied Molecular Genetics is incorporated

   Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

8. 1983Amgen

   Nasdaq listing and the erythropoietin clone

   Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

9. 1984Amgen

   Kirin-Amgen joint venture formed

   Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

10. 1985Amgen

    G-CSF cloned, leading to Neupogen

    While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

11. 1987BP

    UK Government Privatization Complete

    The Thatcher government completes the privatization of its remaining 31.5% stake in BP through a global share offering timed for October 1987 weeks before the global stock market crash known as Black Monday disrupted the sale and left underwriters with unsold…

12. 1989Amgen

    FDA approves Epogen

    The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

13. 1991Amgen

    Neupogen approved, giving Amgen a second franchise

    The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

14. 1991Amgen

    Amgen wins the erythropoietin patent fight

    On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

15. 1998BP

    Merger with Amoco Corporation

    BP merges with Chicago-based Amoco Corporation in a deal valued at approximately $48.2 billion the largest industrial merger in history at the time.

16. 2000BP

    Beyond Petroleum Rebrand

    Under then-CEO Sir John Browne, BP launches the 'Beyond Petroleum' rebranding campaign, introducing the sunflower logo still in use today and publicly positioning the company as an energy company committed to addressing climate change.

17. 2001Amgen

    FDA approves Aranesp, the longer-acting EPO

    Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

18. 2002Amgen

    US$16 billion Immunex acquisition brings Enbrel in-house

    Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

19. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

20. 2010BP

    Deepwater Horizon Disaster

    The Deepwater Horizon drilling rig, operating on the Macondo well in the Gulf of Mexico under contract to BP, suffers a catastrophic blowout on April 20, 2010, killing 11 workers and triggering the largest marine oil spill in US history approximately 4.9 milli…

21. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

22. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

23. 2020BP

    Net-Zero Commitment and Dividend Cut

    Under new CEO Bernard Looney, BP sets a net-zero ambition for 2050 and, in August 2020, pledges to cut oil and gas production by 40% by 2030 and raise low-carbon investment to about $5 billion a year.

24. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

25. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

26. 2024BP

    Auchincloss Confirmed as CEO

    Murray Auchincloss, BP's CFO since 2020 and interim chief since Bernard Looney's September 2023 exit, is confirmed as permanent CEO in January 2024.

27. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

28. 2025BP

    Strategy Reset and Bumerangue Discovery

    In February 2025 BP cuts planned transition investment to $1.5-2 billion a year, raises upstream spending to about $10 billion a year and targets $20 billion of divestments and $14-18 billion of net debt by 2027.

29. 2025BP

    CEO Change and Castrol Sale Agreed

    On December 17, 2025 BP says Murray Auchincloss will step down and names Woodside Energy CEO Meg O'Neill as his successor from April 2026, with Carol Howle as interim CEO.

30. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

31. 2026BP

    O'Neill Takes Over and Simplifies BP

    Meg O'Neill becomes CEO on April 1, 2026. The board removes chair Albert Manifold on May 26 over governance and conduct concerns and names Ian Tyler interim chair, confirming him as permanent chair on September 2.

Acquisitions

Questions about Amgen vs BP